Aardvark Therapeutics, Inc. (AARD) competitors & alternatives
Health Care · NASDAQ
Aardvark Therapeutics, Inc. (AARD)'s top competitors and alternatives — its most similar public companies — include Fractyl Health, Inc. (GUTS), LINEAGE CELL THERAPEUTICS INC (LCTX), TENAX THERAPEUTICS INC (TENX), EVOMMUNE INC (EVMN), VOR BIOPHARMA INC (VOR), AVALYN PHARMA INC (AVLN), ANAPTYSBIO INC (ANAB), Hemab Therapeutics Holdings, Inc. (COAG), RELAY THERAPEUTICS INC (RLAY), HARMONY BIOSCIENCES HLDG INC (HRMY), RELMADA THERAPEUTICS INC (RLMD) and SPRUCE BIOSCIENCES INC (SPRB). These are Aardvark Therapeutics, Inc.'s closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top AARD competitors & alternatives
-
Fractyl Health, Inc.GUTSHealth Care
Fractyl Health is a clinical-stage medical device and gene therapy company developing the Revita mucosa resurfacing procedure and Rejuva gene therapy platform…
$0.76 (as of 2026-07-22) · market cap $123M
-
LINEAGE CELL THERAPEUTICS INCLCTXHealth Care
Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships…
$1.11 (as of 2026-07-22) · market cap $278M
-
TENAX THERAPEUTICS INCTENXHealth Care
A Phase 3 development-stage pharmaceutical company developing novel cardiopulmonary therapies, primarily levosimendan for pulmonary hypertension and imatinib…
$14.79 (as of 2026-07-22) · market cap $418M
-
EVOMMUNE INCEVMNHealth Care
Evommune is a clinical-stage biotechnology company developing novel treatments for inflammatory diseases, currently advancing a pipeline of product candidates…
$11.40 (as of 2026-07-22) · market cap $439M
-
VOR BIOPHARMA INCVORHealth Care
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
$19.51 (as of 2026-07-22) · market cap $1.1B
-
AVALYN PHARMA INCAVLNHealth Care
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled drug formulations for the treatment of rare respiratory diseases.
$28.72 (as of 2026-07-22) · market cap $1.3B
-
ANAPTYSBIO INCANABHealth Care
AnaptysBio is an immunotherapy company generating revenue from blockbuster royalties (Jemperli with GSK, imsidolimab with Vanda) while pursuing its own…
$52.61 (as of 2026-07-22) · market cap $1.6B
-
Hemab Therapeutics Holdings, Inc.COAGHealth Care
Hemab Therapeutics is a clinical-stage biotechnology company developing innovative bispecific and monovalent antibody therapies for serious, rare blood…
$49.23 (as of 2026-07-22) · market cap $2.3B
-
RELAY THERAPEUTICS INCRLAYHealth Care
A precision medicine company using computational drug discovery to target protein motion and advance a pipeline of novel small molecule therapeutics.
$19.27 (as of 2026-07-22) · market cap $4.2B
-
HARMONY BIOSCIENCES HLDG INCHRMYHealth Care
Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor…
$34.86 (as of 2026-07-22) · market cap $2.0B
-
RELMADA THERAPEUTICS INCRLMDHealth Care
Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead…
$5.00 (as of 2026-07-22) · market cap $524M
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
Not quite? Describe exactly what you want →
Peers are Aardvark Therapeutics, Inc.'s closest public companies by shared sub-industry, sector and business themes. See the full profile: Aardvark Therapeutics, Inc. (AARD).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.